Search

Your search keyword '"Malmberg, Anna"' showing total 4 results
Start Over Author "Malmberg, Anna" Journal journal of medicinal chemistry
4 results on '"Malmberg, Anna"'

1. AZD0284, a Potent, Selective, and Orally Bioavailable Inverse Agonist of Retinoic Acid Receptor-Related Orphan Receptor C2

Author

Narjes, Frank, primary, Llinas, Antonio, additional, von Berg, Stefan, additional, Jirholt, Johan, additional, Lever, Sarah, additional, Pehrson, Rikard, additional, Collins, Mia, additional, Malmberg, Anna, additional, Svanberg, Petter, additional, Xue, Yafeng, additional, Olsson, Roine I., additional, Malmberg, Jesper, additional, Hughes, Glyn, additional, Hossain, Nafizal, additional, Grindebacke, Hanna, additional, Leffler, Agnes, additional, Krutrök, Nina, additional, Bäck, Elisabeth, additional, Ramnegård, Marie, additional, Lepistö, Matti, additional, Thunberg, Linda, additional, Aagaard, Anna, additional, McPheat, Jane, additional, Hansson, Eva L., additional, Chen, Rongfeng, additional, Xiong, Yao, additional, and Hansson, Thomas G., additional

Published
2021
Full Text
View/download PDF

2. Discovery of the Oral Leukotriene C4 Synthase Inhibitor (1S,2S)-2-({5-[(5-Chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic Acid (AZD9898) as a New Treatment for Asthma

Author

Munck af Rosenschöld, Magnus, primary, Johannesson, Petra, additional, Nikitidis, Antonios, additional, Tyrchan, Christian, additional, Chang, Hui-Fang, additional, Rönn, Robert, additional, Chapman, Dave, additional, Ullah, Victoria, additional, Nikitidis, Grigorios, additional, Glader, Pernilla, additional, Käck, Helena, additional, Bonn, Britta, additional, Wågberg, Fredrik, additional, Björkstrand, Eva, additional, Andersson, Ulf, additional, Swedin, Linda, additional, Rohman, Mattias, additional, Andreasson, Theresa, additional, Bergström, Eva Lamm, additional, Jiang, Fanyi, additional, Zhou, Xiao-Hong, additional, Lundqvist, Anders J., additional, Malmberg, Anna, additional, Ek, Margareta, additional, Gordon, Euan, additional, Pettersen, Anna, additional, Ripa, Lena, additional, and Davis, Andrew M., additional

Published
2019
Full Text
View/download PDF

3. Discovery of the Oral Leukotriene C4 Synthase Inhibitor (1S,2S)-2-({5-[(5-Chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic Acid (AZD9898) as a New Treatment for Asthma

Author

Munck af Rosenschöld, Magnus, Johannesson, Petra, Nikitidis, Antonios, Tyrchan, Christian, Chang, Hui-Fang, Rönn, Robert, Chapman, Dave, Ullah, Victoria, Nikitidis, Grigorios, Glader, Pernilla, Käck, Helena, Bonn, Britta, Wågberg, Fredrik, Björkstrand, Eva, Andersson, Ulf, Swedin, Linda, Rohman, Mattias, Andreasson, Theresa, Bergström, Eva Lamm, Jiang, Fanyi, Zhou, Xiao-Hong, Lundqvist, Anders J., Malmberg, Anna, Ek, Margareta, Gordon, Euan, Pettersen, Anna, Ripa, Lena, and Davis, Andrew M.

Abstract

While bronchodilators and inhaled corticosteroids are the mainstay of asthma treatment, up to 50% of asthmatics remain uncontrolled. Many studies show that the cysteinyl leukotriene cascade remains highly activated in some asthmatics, even those on high-dose inhaled or oral corticosteroids. Hence, inhibition of the leukotriene C4 synthase (LTC4S) enzyme could provide a new and differentiated core treatment for patients with a highly activated cysteinyl leukotriene cascade. Starting from a screening hit (3), a program to discover oral inhibitors of LTC4S led to (1S,2S)-2-({5-[(5-chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic acid (AZD9898) (36), a picomolar LTC4S inhibitor (IC50= 0.28 nM) with high lipophilic ligand efficiency (LLE = 8.5), which displays nanomolar potency in cells (peripheral blood mononuclear cell, IC50,free= 6.2 nM) and good in vivo pharmacodynamics in a calcium ionophore-stimulated rat model after oral dosing (in vivo, IC50,free= 34 nM). Compound 36mitigates the GABA binding, hepatic toxicity signal, and in vivo toxicology findings of an early lead compound 7with a human dose predicted to be 30 mg once daily.

Published
2024
Full Text
View/download PDF

4. Discovery of the Oral Leukotriene C4 Synthase Inhibitor (1 S ,2 S )-2-({5-[(5-Chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic Acid (AZD9898) as a New Treatment for Asthma.

Author

Munck Af Rosenschöld M, Johannesson P, Nikitidis A, Tyrchan C, Chang HF, Rönn R, Chapman D, Ullah V, Nikitidis G, Glader P, Käck H, Bonn B, Wågberg F, Björkstrand E, Andersson U, Swedin L, Rohman M, Andreasson T, Bergström EL, Jiang F, Zhou XH, Lundqvist AJ, Malmberg A, Ek M, Gordon E, Pettersen A, Ripa L, and Davis AM

Subjects
Administration, Oral, Animals, Anti-Asthmatic Agents administration & dosage, Anti-Asthmatic Agents chemistry, Asthma metabolism, Disease Models, Animal, Dose-Response Relationship, Drug, Enzyme Inhibitors administration & dosage, Enzyme Inhibitors chemistry, Glutathione Transferase metabolism, Humans, Molecular Structure, Pyrazines chemical synthesis, Pyrazines chemistry, Rats, Structure-Activity Relationship, Anti-Asthmatic Agents pharmacology, Asthma drug therapy, Drug Discovery, Enzyme Inhibitors pharmacology, Glutathione Transferase antagonists & inhibitors, Pyrazines pharmacology
Abstract

While bronchodilators and inhaled corticosteroids are the mainstay of asthma treatment, up to 50% of asthmatics remain uncontrolled. Many studies show that the cysteinyl leukotriene cascade remains highly activated in some asthmatics, even those on high-dose inhaled or oral corticosteroids. Hence, inhibition of the leukotriene C4 synthase (LTC4S) enzyme could provide a new and differentiated core treatment for patients with a highly activated cysteinyl leukotriene cascade. Starting from a screening hit ( 3 ), a program to discover oral inhibitors of LTC4S led to (1 S ,2 S )-2-({5-[(5-chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic acid (AZD9898) ( 36 ), a picomolar LTC4S inhibitor (IC 50 = 0.28 nM) with high lipophilic ligand efficiency (LLE = 8.5), which displays nanomolar potency in cells (peripheral blood mononuclear cell, IC 50,free = 6.2 nM) and good in vivo pharmacodynamics in a calcium ionophore-stimulated rat model after oral dosing (in vivo, IC 50,free = 34 nM). Compound 36 mitigates the GABA binding, hepatic toxicity signal, and in vivo toxicology findings of an early lead compound 7 with a human dose predicted to be 30 mg once daily.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results